Commodore Capital’s Tango Therapeutics TNGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-2,250,000
Closed -$70.3M – 41
2026
Q2
$70.3M Buy
+2,250,000
New +$55.6M 4.19% 9
2025
Q4
– Sell
-1,500,000
Closed -$12.6M – 40
2025
Q3
$12.6M Hold
1,500,000
– – 0.62% 28
2025
Q2
$7.68M Buy
+1,500,000
New +$3.71M 0.54% 29

Other funds holding TNGX

Commodore Capital's TNGX Position: Q3 2026 in Review

Commodore Capital sold out of Tango Therapeutics (TNGX) in Q3 2026, closing a stake of 2,250,000 shares — an estimated $70.3M sold.

Commodore Capital first reported a position in TNGX in Q2 2025 and held it in 3 quarters. The position peaked at $70.3M in Q2 2026. 246 funds tracked by Wall St. Rank hold TNGX as of Q3 2026.

  • Commodore Capital reported no remaining Tango Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Commodore Capital sold 2,250,000 Tango Therapeutics shares in Q3 2026, an estimated $70.3M.
  • Commodore Capital first reported a position in Tango Therapeutics in Q2 2025 and held it in 3 quarters.
  • Commodore Capital's Tango Therapeutics position peaked at $70.3M in Q2 2026.
  • 246 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2026.

Based on Commodore Capital's 13F filing for Q3 2026, filed 16 Nov 2026.